Gaps and discontinuation of statin treatment in Norway: potential for optimizing management of lipid lowering drugs.
Ingrid EngebretsenJohn MunkhaugenChristoffer BuggeSigrun HalvorsenKristina Malene ØdegaardEeva-Liisa Røssell JohansenIvar Sønbø KristiansenPublished in: European heart journal open (2022)
There is a great potential for improving drug adherence and optimizing lipid lowering therapy by switching to more effective statins in greater doses, and more often add ezetimibe and PCSK9 inhibitors to treatment.